Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy

BACKGROUND: Adjuvant chemotherapy after the resection of stage IB-IIIA non-small cell lung cancer (NSCLC) is now the standard of care based on large-scale phase III trials and a meta-analysis. However, chemotherapy has plateaued in terms of its efficacy, and the search for treatment prediction bioma...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Katsuhiko, Yukawa, Takuro, Okita, Riki, Saisho, Shinsuke, Maeda, Ai, Nojima, Yuji, Nakata, Masao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4332968/
https://www.ncbi.nlm.nih.gov/pubmed/25888998
http://dx.doi.org/10.1186/s12957-014-0426-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4332968/
https://www.ncbi.nlm.nih.gov/pubmed/25888998
http://dx.doi.org/10.1186/s12957-014-0426-0

Ejemplares similares